Sector News

Pfizer bags CMV vaccine with Redvax buy

January 5, 2015
Life sciences
Pfizer has acquired a controlling interest in Redvax, a spin-off from Switzerland’s Redbiotec, giving it access to a preclinical human cytomegalovirus vaccine candidate.
 
The transaction, the financial details for which have not been disclosed, includes intellectual property and a technology platform related to a second, undisclosed vaccine programme. CMV is a herpes virus and one out of every five children born with infection may experience hearing loss and severe neurologic disorders.
 
Pfizer noted that more children have disabilities due to congenital CMV than “other well-known infections and syndromes”, including Down syndrome, fetal alcohol syndrome, spina bifida and paediatric HIV/AIDS. It also cited the Institute of Medicine’s ranking of the development of a CMV vaccine as a highest priority; the estimated costs associated with the disease for the US healthcare system is at least $1.86 billion annually, more than $300,000 per child.
 
Kathrin Jansen, head of vaccine research and early development at Pfizer, said that with the acquisition of Redvax, “we will seek to develop a vaccine to prevent a difficult disease that can have a devastating and lifelong impact on young children.”
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”